Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Expectations By $0.21 EPS

Dogwood Therapeutics (NASDAQ:DWTX) announced its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.21), FiscalAI reports.

Dogwood Therapeutics Trading Up 2.5%

DWTX traded up $0.05 during midday trading on Thursday, hitting $1.97. 18,537 shares of the company traded hands, compared to its average volume of 76,791. The company has a market capitalization of $66.35 million, a price-to-earnings ratio of -0.19 and a beta of 1.71. Dogwood Therapeutics has a 52-week low of $1.28 and a 52-week high of $9.50. The business has a 50 day simple moving average of $1.55 and a two-hundred day simple moving average of $2.05.

Institutional Trading of Dogwood Therapeutics

A hedge fund recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics as of its most recent SEC filing. 9.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on DWTX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Friday, July 24th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Dogwood Therapeutics in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Dogwood Therapeutics has an average rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.